<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02474537</url>
  </required_header>
  <id_info>
    <org_study_id>CINC280A2106</org_study_id>
    <nct_id>NCT02474537</nct_id>
  </id_info>
  <brief_title>INC280 in Healthy Subjects With Impaired Hepatic Function and Subjects With Normal Hepatic Function</brief_title>
  <official_title>An Open Label, Single-dose, Multi-center, Parallel-group, Two-staged Study to Evaluate Pharmacokinetics of Oral cMET Inhibitor INC280 in Non-Cancer Subjects With Impaired Hepatic Function and Non-Cancer Subjects With Normal Hepatic Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase I, multi-center, open-label, single oral dose, parallel group study to&#xD;
      evaluate the pharmacokinetics and safety of INC280 in non-cancer subjects with impaired&#xD;
      hepatic function and non-cancer subjects with normal hepatic function.The study population&#xD;
      will be healthy male and postmenopausal or sterile female subjects who meet all of the&#xD;
      inclusion and none of the exclusion criteria. Subjects will be assigned to groups according&#xD;
      to their hepatic function: normal (Group 1), mild (Group 2), moderate (Group 3), and severe&#xD;
      (Group 4) impairment. This study consists of a two-staged design with interim analysis. In&#xD;
      Stage 1, subjects in Groups 1, 2 and 3 will be enrolled. Upon completion of Stage 1, an&#xD;
      interim analysis will be conducted. Depending on the results of the analysis, either the&#xD;
      study will conclude with no further enrollment or Stage 2 will commence with enrollment of&#xD;
      Group 4.&#xD;
&#xD;
      A minimum of 6 evaluable subjects per group will be enrolled.Once enrolled in the study,&#xD;
      participants will be confined to the facility for 4 days, given a single dose of INC280 and&#xD;
      monitored for pharmacokinetic and safety assessments.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 12, 2015</start_date>
  <completion_date type="Actual">September 12, 2017</completion_date>
  <primary_completion_date type="Actual">August 14, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUClast of INC280</measure>
    <time_frame>Up to 72 hours post-dose</time_frame>
    <description>INC280 pharmacokinetic parameters</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUCinf of INC280</measure>
    <time_frame>Up to 72 hours post-dose</time_frame>
    <description>INC280 pharmacokinetic parameters</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of INC280</measure>
    <time_frame>Up to 72 hours post-dose</time_frame>
    <description>INC280 pharmacokinetic parameters</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax of INC280</measure>
    <time_frame>Up to 72 hours post-dose</time_frame>
    <description>INC280 pharmacokinetic parameters</description>
  </primary_outcome>
  <primary_outcome>
    <measure>T1/2 of INC280</measure>
    <time_frame>Up to 72 hours post-dose</time_frame>
    <description>INC280 pharmacokinetic parameters</description>
  </primary_outcome>
  <primary_outcome>
    <measure>CL/F of INC280</measure>
    <time_frame>Up to 72 hours post-dose</time_frame>
    <description>INC280 pharmacokinetic parameters</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Vz/F of INC280</measure>
    <time_frame>Up to 72 hours post-dose</time_frame>
    <description>INC280 pharmacokinetic parameters</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events based on the CTCAE v4.03 grade (severity) and frequency, and other safety data (e.g., ECG, laboratory results)</measure>
    <time_frame>Up to 30 days</time_frame>
    <description>Safety</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Unbound fraction and AUClast based on unbound concentration in plasma</measure>
    <time_frame>3 hours post-dose</time_frame>
    <description>To assess the plasma protein binding of INC280</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Unbound fraction and AUCinf based on unbound concentration in plasma</measure>
    <time_frame>3 hours post-dose</time_frame>
    <description>To assess the plasma protein binding of INC280</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Unbound fraction and Cmax based on unbound concentration in plasma</measure>
    <time_frame>3 hours post-dose</time_frame>
    <description>To assess the plasma protein binding of INC280</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Unbound fraction and Tmax based on unbound concentration in plasma</measure>
    <time_frame>3 hours post-dose</time_frame>
    <description>To assess the plasma protein binding of INC280</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Unbound fraction and T1/2 based on unbound concentration in plasma</measure>
    <time_frame>3 hours post-dose</time_frame>
    <description>To assess the plasma protein binding of INC280</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Unbound fraction and CL/F based on unbound concentration in plasma</measure>
    <time_frame>3 hours post-dose</time_frame>
    <description>To assess the plasma protein binding of INC280</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Unbound fraction and Vz/F based on unbound concentration in plasma</measure>
    <time_frame>3 hours post-dose</time_frame>
    <description>To assess the plasma protein binding of INC280</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Hepatic Impairment</condition>
  <arm_group>
    <arm_group_label>Normal hepatic function</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects with normal hepatic function</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mild hepatic impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects with mild hepatic impairment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Moderate hepatic impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects with moderate hepatic impairment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Severe hepatic impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects with severe hepatic impairment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>INC280</intervention_name>
    <description>Single 200 mg dose INC280</description>
    <arm_group_label>Mild hepatic impairment</arm_group_label>
    <arm_group_label>Moderate hepatic impairment</arm_group_label>
    <arm_group_label>Normal hepatic function</arm_group_label>
    <arm_group_label>Severe hepatic impairment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria (all groups):&#xD;
&#xD;
          -  Female subjects must be postmenopausal or sterile&#xD;
&#xD;
          -  Good health, as determined by absence of clinically significant findings in medical&#xD;
             history, physical examination, vital signs, and ECGs, unless it is consistent with&#xD;
             known clinical disease for hepatic impairment subjects&#xD;
&#xD;
          -  Adequate organ function and normal laboratory tests, unless it is consistent with&#xD;
             known clinical disease for hepatic impairment subjects&#xD;
&#xD;
          -  Body Mass Index (BMI) of 18- 36 kg/m2, with body weight ≥ 50 kg&#xD;
&#xD;
        Inclusion Criteria (hepatic impairment groups):&#xD;
&#xD;
          -  Confirmed liver disease&#xD;
&#xD;
          -  Stable comorbidities are allowed as long as generally considered healthy&#xD;
&#xD;
          -  Subjects with hepatic impairment must meet the following laboratory values:&#xD;
&#xD;
          -  Aspartate transaminase (AST) ≤ 5 x ULN&#xD;
&#xD;
          -  Alanine transaminase (ALT) ≤ 5 x ULN&#xD;
&#xD;
          -  Total bilirubin ≤ 3 x ULN (≤ 5 x XULN for subjects with severe hepatic impairment&#xD;
             [group 4])&#xD;
&#xD;
          -  Calculated creatinine clearance (using Cockcroft-Gault formula) ≥ 45 mL/min&#xD;
&#xD;
          -  Platelets &gt; 50 x 10^9/L. Subjects with severe hepatic impairment can be enrolled if&#xD;
             platelet count &gt; 40 x 10^9/L&#xD;
&#xD;
        Exclusion Criteria (all groups):&#xD;
&#xD;
          -  History or presence of clinically significant ECG abnormalities or clinically&#xD;
             significant cardiovascular disease&#xD;
&#xD;
          -  Immunocompromised subjects, including HIV&#xD;
&#xD;
          -  Use of drugs known to affect CYP3A4&#xD;
&#xD;
          -  Use of QT-prolonging drugs&#xD;
&#xD;
          -  Use of any other drugs, unless they are required to treat the hepatic impairment&#xD;
             subject's disease&#xD;
&#xD;
          -  Use of proton pump inhibitors (PPI) medications within 7 days prior to dosing and&#xD;
             during the current study until last day of confinement&#xD;
&#xD;
        Exclusion Criteria (normal hepatic function group):&#xD;
&#xD;
          -  A positive Hepatitis B surface antigen (HBsAg) or Hepatitis C test result&#xD;
&#xD;
        Exclusion Criteria (hepatic impairment groups):&#xD;
&#xD;
          -  Active Grade 3 or 4 hepatic encephalopathy within 4 weeks of study entry&#xD;
&#xD;
          -  Clinical evidence of severe ascites&#xD;
&#xD;
          -  Ascites requiring paracentesis within 3 weeks prior to dosing&#xD;
&#xD;
        Other protocol-defined inclusion/exclusion criteria may apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>NovartisPharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>NovartisPharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Miami Miller School of Medicine Clinical Resea Oncology</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Pharmacology of Miami, LLC.</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33142</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Orlando Clinical Research Center</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32086</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DaVita Clinical Research</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center Oncology</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=17140</url>
    <description>Results for CINC280A2106 can be found on the Novartis Clinical Trial Results website</description>
  </link>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>June 9, 2015</study_first_submitted>
  <study_first_submitted_qc>June 16, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 17, 2015</study_first_posted>
  <last_update_submitted>December 8, 2020</last_update_submitted>
  <last_update_submitted_qc>December 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>hepatic impairment,</keyword>
  <keyword>INC280,</keyword>
  <keyword>Oral cMET Inhibitor,</keyword>
  <keyword>Non-Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

